Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan

Antiviral Research

Volumn 75, Issue 1, 2007, Pages 75-82

  Gatanaga, Hiroyuki ^a   Ibe, Shiro ^b   Matsuda, Masakazu ^c   Yoshida, Shigeru ^d   Asagi, Tsukasa ^e   Kondo, Makiko ^f   Sadamasu, Kenji ^g   Tsukada, Hiroki ^h   Masakane, Aki ⁱ   Mori, Haruyo ^j   Takata, Noboru ^k   Minami, Rumi ^e   Tateyama, Masao ^l   Koike, Takao ^d   Itoh, Toshihiro ^e   Imai, Mitsunobu ^f   Nagashima, Mami ^g   Gejyo, Fumitake ^h   Ueda, Mikio ⁱ   Hamaguchi, Motohiro ^b   Kojima, Yoko ^j   Shirasaka, Takuma ^e   Kimura, Akiro ^k   Yamamoto, Masahiro ^e   Fujita, Jiro ^l   Oka, Shinichi ^a   Sugiura, Wataru ^c   more..

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

^f KANAGAWA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^g TOKYO METROPOLITAN INSTITUTE OF PUBLIC HEALTH   (Japan)

^h NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

ⁱ ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^j OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^k HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^l UNIVERSITY OF THE RYUKYUS   (Japan)

more..

Author keywords

Drug resistance; HIV 1; Japan; Newly infected

Indexed keywords

RNA DIRECTED DNA POLYMERASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CODON; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GENOTYPE; HEALTH SURVEY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ACUTE DISEASE; ADULT; BLOTTING, WESTERN; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DATA COLLECTION; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MUTATION; PREVALENCE; RISK-TAKING; VIRAL LOAD;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34247268470     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.11.012     Document Type: Article

References (44)

1. Aberg J.A., Gallant J.E., Anderson J., Oleske J.M., Libman H., Currier J.S., Stone V.E., Kaplan J.E., and HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 39 (2004) 609-629
2. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 44 (2006) S6-S9
3. Ammassari A., Antinori A., Aloisi M.S., Trotta M.P., Murri R., Bartoli L., Monforte A.D., Wu A.W., and Starace F. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 45 (2004) 394-402
4. Ariyoshi K., Matsuda M., Miura H., Tateishi S., Yamada K., and Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J. Acquir. Immune Defic. Syndr. 33 (2003) 336-342
5. Barbour J.D., Hecht F.M., Wrin T., Liegler T.J., Ramstead C.A., Busch M.P., Segal M.R., Petropoulos C.J., and Grant R.M. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 18 (2004) 1683-1689
6. Boden D., Hurley A., Zhang L., Cao Y., Guo Y., Jones E., Tsay J., Ip J., Farthing C., Limoli K., Parkin N., and Markowitz M. HIV-1 drug resistance in newly infected individuals. JAMA 282 (1999) 1135-1141
7. Brook M.G., Gilson R., and Wilkins E.L. BHIVA Guidelines: coinfection with HIV and chronic hepatitis B virus. HIV Med. 4 (2003) S42-S51
8. CASCADE Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-established dates of seroconversion. J. Acquir. Immune Defic. Syndr. 34 (2003) 76-83
9. Chaix M.L., Descamps D., Harzic M., Schneider V., Deveau C., Tamalet C., Pellegrin I., Izopet J., Ruffault A., Masquelier B., Meyer L., Rouzioux C., Brun-Vézinet F., and Costagliola D. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 17 (2003) 2635-2643
10. Cornelissen M., van den Burg R., Zorgdrager F., Lukashov V., and Goudsmit J. pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J. Virol. 71 (1997) 6348-6358
11. Descamps D., Chaix M.L., Andre P., Brodard V., Cottalorda J., Deveau C., Harzic M., Ingrand D., Izopet J., Kohli E., Masquelier B., Mouajjah S., Palmer P., Pellegrin I., Plantier J.C., Poggi C., Rogez S., Ruffault A., Schneider V., Signori-Schmuck A., Tamalet C., Wirden M., Rouzioux C., Brun-Vézinet F., Meyer L., and Costagliola D. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naïve chronically infected patients in 2001-2002. J. Acquir. Immune Defic. Syndr. 38 (2005) 545-552
12. Garcia-Lerma J.G., Nidtha S., Blumoff K., Weinstock H., and Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13907-13912
13. Gatanaga H., Yasuoka A., Kikuchi Y., Tachikawa N., and Oka S. Influence of prior HIV-1 infection on the development of chronic hepatitis B infection. Eur. J. Clin. Microbiol. Infect. Dis. 19 (2000) 237-239
14. Hachiya A., Gatanaga H., Kodama E., Ikeuchi M., Matsuoka M., Harada S., Mitsuya H., Kimura S., and Oka S. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naive patients. Virology 327 (2004) 215-224
15. Ibe S., Hotta N., Takeo U., Tawada Y., Mamiya N., Yamanaka K., Utsumi M., and Kaneda T. Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naive patients and usefulness of genotype testing. Microbiol. Immunol. 47 (2003) 499-505
16. Jayaraman G.C., Archibald C.P., Kim J., Rekart M.L., Singh A.E., Harmen S., Wood M., and Sandstrom P. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J. Acquir. Immune Defic. Syndr. 42 (2006) 86-90
17. Johnson V.A., Brun-Vézinet F., Clotet B., Conway B., Kuritzkes D.R., Pillay D., Schapiro J.M., Telenti A., and Richman D.D. Update of the drug resistance mutations in HIV-1: fall 2005. Top. HIV Med. 13 (2005) 125-131
18. Johnson V.A., Brun-Vézinet F., Clotet B., Kuritzkes D.R., Pillay D., Schapiro J.M., and Richman D.D. Update of the drug resistance mutations in HIV-1: fall 2006. Top. HIV Med. 14 (2006) 125-130
19. Kellerman S.E., Hanson D.L., McNaghten A.D., and Fleming P.L. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J. Infect. Dis. 188 (2003) 571-577
20. Kobayashi M., Suzuki F., Arase Y., Akuta N., Suzuki Y., Hosaka T., Saitoh S., Kobayashi M., Tsubota A., Someya T., Ikeda K., Matsuda M., Sato J., and Kumada H. Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001. J. Gastroenterol. 39 (2004) 844-850
21. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellmann N.S., and Richman D.D. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347 (2002) 385-394
22. Moss A.R., Hahn J.A., Perry S., Charlebois E.D., Guzman D., Clark R.A., and Bangsberg D.R. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin. Infect. Dis. 39 (2004) 1190-1198
23. Novak R.M., Chen L., MacArthur R.D., Baxter J.D., Huppler Hullsiek K., Peng G., Xiang Y., Henely C., Schmetter B., Uy J., van den Berg-Wolf M., Kozal M., and Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin. Infect. Dis. 40 (2005) 468-474
24. Orito E., Ichida T., Sakugawa H., Sata M., Horiike N., Hino K., Okita K., Okanoue T., Iino S., Tanaka E., Suzuki K., Watanabe H., Hige S., and Mizokami M. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34 (2001) 590-594
25. Palepu A., Tyndall M.W., Chan K., Wood E., Montaner J.S., and Hogg R.S. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir. Ther. 9 (2004) 713-719
26. Perno C.F., Cozzi-Lepri A., Balotta C., Bertoli A., Violin M., Monno L., Zauli T., Montroni M., Ippolito G., d'Arminio-Monforte A., and I.CO.N.A Study Group. Low prevalence of primary mutations associated with drug resistance in antiviral-naïve patients at therapy initiation. AIDS 16 (2002) 619-624
27. Puoti M., Torti C., Bruno R., Filice G., and Carosi G. Natural history of chronic hepatitis B in co-infected patients. J. Hepatol. 44 (2006) S65-S70
28. Quinones-Mateu M.E., Albright J.L., Mas A., Soriano V., and Arts E.J. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. J. Virol. 72 (1998) 9002-9015
29. Richman D.D. HIV chemotherapy. Nature 410 (2001) 995-1001
30. Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., and Bozzette S.A. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
31. Romano L., Venturi G., Ferruzzi R., Riccio M.L., Corsi P., Leoncini F., Vinattieri A., Incandela L., Valensin P.E., and Zazzi M. Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy. AIDS 14 (2000) 2204-2206
32. Romano L., Venturi G., Bloor S., Harrigan R., Larder B.A., Major J.C., and Zazzi M. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J. Infect. Dis. 185 (2002) 898-904
33. Shafer, R.W., Rhee, S.Y., Pillay, D., Miller, V., Sandstrom, P., Schapiro, J.M., Kuritzkes, D.R., Bennett, D., 2006. HIV-1 RT and protease mutations for HIV-1 drug resistance surveillance and epidemiology: application to published studies of primary infection. Stanford HIV Drug Resistance Database, http://hivdb.stanford.edu
34. Shibayama T., Masuda G., Ajisawa A., Hiruma K., Tsuda F., Nishizawa T., Takahashi M., and Okamoto H. Characterization of seven genotypes (A to E G and H) of hepatitis B virus recovered from Japanese patients infected with human immunodeficiency virus type 1. J. Med. Virol. 76 (2005) 24-32
35. Simon V., Vanderhoeven J., Hurley A., Ramratnam B., Louie M., Dawson K., Parkin N., Boden D., and Markowitz M. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 16 (2002) 1511-1519
36. Snoeck J., Kantor R., Shafer R.W., Van Laethem K., Deforche K., Carvalho A.P., Wynhoven B., Soares M.A., Cane P., Clarke J., Pillay C., Sirivichayakul S., Ariyoshi K., Holguin A., Rudich H., Rodrigues R., Bouzas M.B., Brun-Vézinet F., Reid C., Cahn P., Brigido L.F., Grossman Z., Soriano V., Sugiura W., Phanuphak P., Morris L., Weber J., Pillay D., Tanuri A., Harrigan R.P., Camacho R., Schapiro J.M., Katzenstein D., and Vandamme A.M. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob. Agents Chemother. 50 (2006) 694-701
37. Strader D.B. Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. Clin. Infect. Dis. 41 (2005) S7-S13
38. Sugiura W. Effect of introduction of highly active antiretroviral treatment and the changes in patterns of drug-resistant HIV-1 in Japan. J. Infect. Chemother. 7 (2001) 127-132
39. Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. Br. Med. J. 322 (2001) 1087-1088
40. Vandamme A.M., Sonnerborg A., Ait-Khaled M., Albert J., Asjo B., Bacheler L., Banhegyi D., Boucher C., Brun-Vézinet F., Camacho R., Clevenbergh P., Clumeck N., Dedes N., De Luca A., Doerr H.W., Faudon J.L., Gatti G., Gerstoft J., Hall W.W., Hatzakis A., Hellmann N., Horban A., Lundgren J.D., Kempf D., Miller M., Miller V., Myers T.W., Nielsen C., Opravil M., Palmisano L., Perno C.F., Phillips A., Pillay D., Pumarola T., Ruiz L., Salminen M., Schapiro J., Schmidt B., Schmit J.C., Schuurman R., Shulse E., Soriano V., Staszewski S., Vella S., Youle M., Ziermann R., and Perrin L. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir. Ther. 9 (2004) 829-848
41. Violin M., Cozzi-Lepri A., Velleca R., Vincenti A., D'Elia S., Chiodo F., Ghinelli F., Bertoli A., d'Arminio Monforte A., Perno C.F., Moroni M., and Balotta C. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 18 (2004) 227-235
42. Walter H., Schmidt B., Werwein M., Schwingel E., and Korn K. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob. Agents Chemother. 46 (2002) 89-94
43. Weinstein M.C., Goldie S.J., Losina E., Cohen C.J., Baxter J.D., Zhang H., Kimmel A.D., and Freedberg K.A. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann. Intern. Med. 134 (2001) 440-450
44. Weinstock H.S., Zaidi I., Heneine W., Bennett D., Garcia-Lerma J.G., Douglas Jr. J.M., LaLota M., Dickinson G., Schwarcz S., Torian L., Wendell D., Paul S., Goza G.A., Ruiz J., Boyett B., and Kaplan J.E. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J. Infect. Dis. 189 (2004) 2174-2180